In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y.
Publication
, Journal Article
Kelsey, MD; Newby, LK
Published in: Ann Intern Med
November 2022
Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 202;400:380-90. 35863366.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
November 2022
Volume
175
Issue
11
Start / End Page
JC126
Location
United States
Related Subject Headings
- Treatment Outcome
- Randomized Controlled Trials as Topic
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Humans
- General & Internal Medicine
- Ezetimibe
- Equivalence Trials as Topic
- Drug Therapy, Combination
- Atherosclerosis
- Anticholesteremic Agents
Citation
APA
Chicago
ICMJE
MLA
NLM
Kelsey, M. D., & Newby, L. K. (2022). In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y. Ann Intern Med, 175(11), JC126. https://doi.org/10.7326/J22-0085
Kelsey, Michelle D., and L Kristin Newby. “In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y.” Ann Intern Med 175, no. 11 (November 2022): JC126. https://doi.org/10.7326/J22-0085.
Kelsey MD, Newby LK. In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y. Ann Intern Med. 2022 Nov;175(11):JC126.
Kelsey, Michelle D., and L. Kristin Newby. “In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y.” Ann Intern Med, vol. 175, no. 11, Nov. 2022, p. JC126. Pubmed, doi:10.7326/J22-0085.
Kelsey MD, Newby LK. In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y. Ann Intern Med. 2022 Nov;175(11):JC126.
Published In
Ann Intern Med
DOI
EISSN
1539-3704
Publication Date
November 2022
Volume
175
Issue
11
Start / End Page
JC126
Location
United States
Related Subject Headings
- Treatment Outcome
- Randomized Controlled Trials as Topic
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Humans
- General & Internal Medicine
- Ezetimibe
- Equivalence Trials as Topic
- Drug Therapy, Combination
- Atherosclerosis
- Anticholesteremic Agents